These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 32426374)
1. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy. Wang L; Zhang Y; Zhang S Front Cardiovasc Med; 2020; 7():78. PubMed ID: 32426374 [TBL] [Abstract][Full Text] [Related]
2. Viral sepsis is a complication in patients with Novel Corona Virus Disease (COVID-19). Liu D; Wang Q; Zhang H; Cui L; Shen F; Chen Y; Sun J; Gan L; Sun J; Wang J; Zhang J; Cai Q; Deng J; Jiang J; Zeng L Med Drug Discov; 2020 Dec; 8():100057. PubMed ID: 32838292 [TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
4. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. Quirch M; Lee J; Rehman S J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537 [TBL] [Abstract][Full Text] [Related]
5. Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology. Yokota S; Miyamae T; Kuroiwa Y; Nishioka K J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33671159 [TBL] [Abstract][Full Text] [Related]
6. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Que Y; Hu C; Wan K; Hu P; Wang R; Luo J; Li T; Ping R; Hu Q; Sun Y; Wu X; Tu L; Du Y; Chang C; Xu G Int Rev Immunol; 2022; 41(2):217-230. PubMed ID: 33616462 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
8. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027 [TBL] [Abstract][Full Text] [Related]
9. Cytokine Storm and Failed Resolution in COVID-19: Taking a Cue from Multiple Sclerosis. Zahoor I; Li Y; Rattan R; Giri S Adv Exp Med Biol; 2021; 1352():211-222. PubMed ID: 35132603 [TBL] [Abstract][Full Text] [Related]
10. Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications? Darwesh AM; Bassiouni W; Sosnowski DK; Seubert JM Pharmacol Ther; 2021 Mar; 219():107703. PubMed ID: 33031856 [TBL] [Abstract][Full Text] [Related]
12. Pathogenesis-directed therapy of 2019 novel coronavirus disease. Stratton CW; Tang YW; Lu H J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355 [TBL] [Abstract][Full Text] [Related]
13. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711 [TBL] [Abstract][Full Text] [Related]
14. Cytokine storm in COVID-19 and parthenolide: Preclinical evidence. Bahrami M; Kamalinejad M; Latifi SA; Seif F; Dadmehr M Phytother Res; 2020 Oct; 34(10):2429-2430. PubMed ID: 32472655 [TBL] [Abstract][Full Text] [Related]
15. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187 [TBL] [Abstract][Full Text] [Related]
16. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P Front Immunol; 2021; 12():589095. PubMed ID: 33995341 [TBL] [Abstract][Full Text] [Related]
18. Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. Leyfman Y; Erick TK; Reddy SS; Galwankar S; Nanayakkara PWB; Di Somma S; Sharma P; Stawicki SP; Chaudry IH Shock; 2020 Oct; 54(4):438-450. PubMed ID: 32649367 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular impact of COVID-19 with a focus on children: A systematic review. Rodriguez-Gonzalez M; Castellano-Martinez A; Cascales-Poyatos HM; Perez-Reviriego AA World J Clin Cases; 2020 Nov; 8(21):5250-5283. PubMed ID: 33269260 [TBL] [Abstract][Full Text] [Related]
20. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Ramasamy S; Subbian S Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]